News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
finance.yahoo.com Market update
Gilead shares are up 35% since Barron’s highlighted them, but our catalysts have yet to fully play out. Continue Reading
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Sware gains 35 years of pharma technology leadership as life sciences organizations modernize validation for the AI era BOSTON, September 29, 2026--(BUSINESS WIRE)--Sware, Inc., the company behind the Res_Q, the AI-powered validation platform, and provider of GxP compliance solutions, today announced the appointment of …
On September 16, Gilead Sciences, Inc. (NASDAQ:GILD) expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to cover an investigational once-yearly formulation for HIV pre-exposure prophylaxis (PrEP). Covering 120 high-incidence, lower-income countries, the expanded framework aims to accelerate manufacturing readiness and …
At first glance, Gilead Sciences, Inc. (NASDAQ:GILD) and Intuitive Surgical, Inc. (NASDAQ:ISRG) don't make for the most obvious comparison. One sells medicines led by a massive HIV franchise, while the other has built its business around robotic surgery. Yet both have given investors a …
Gilead Sciences, Inc. (NASDAQ:GILD) and Danaher Corporation (NYSE:DHR) are both showing signs of stronger growth, but they are getting there in very different ways. Gilead already has momentum, which is supported by its HIV business that is expanding at a double-digit rate, with newer …
Gilead Sciences, Inc. (NASDAQ:GILD) and Thermo Fisher Scientific Inc. (NYSE:TMO) are benefiting from two very different sources of growth. Gilead's momentum is being driven primarily by its HIV portfolio, where established medicines and newer products are expanding rapidly. Thermo Fisher, meanwhile, is beginning to …
Gilead Sciences (GILD) has put fresh numbers on the table, raising its 2026 sales outlook and lifting its quarterly dividend by 3.8%, a combination that tends to grab investor attention. That guidance change is landing in a stock that already has momentum behind it, …
Gilead Sciences, Inc. (NASDAQ:GILD) and Medtronic plc (NYSE:MDT) both combine growing healthcare businesses with regular cash returns to shareholders, but the sources of that growth look very different. Gilead is being propelled by its dominant HIV portfolio, where several products are expanding rapidly. On …
Gilead Sciences, Inc. (NASDAQ:GILD) and Abbott Laboratories (NYSE:ABT) both return cash to shareholders through dividends, but the businesses supporting those payouts look very different. Gilead is currently growing faster, powered by an HIV franchise that continues to gain momentum, while Abbott is offering considerably …
Gilead Sciences, Inc. (NASDAQ:GILD) and Johnson & Johnson (NYSE:JNJ) offer investors two very different versions of pharmaceutical growth. Gilead is expanding faster, powered by an HIV franchise that continues to gain momentum, while Johnson & Johnson isn't growing as quickly, but its portfolio stretches …
Pfizer Inc. (NYSE:PFE) and Gilead Sciences, Inc. (NASDAQ:GILD) present investors with two very different forms of concentration risk. Pfizer needs newer medicines and its pipeline to offset revenue that will increasingly face generic and biosimilar competition, while Gilead has the opposite problem, where its …
In the latest trading session, Gilead Sciences (GILD) closed at $152.67, marking a +1.4% move from the previous day. Meanwhile, the Dow experienced a drop of 0.36%, and the technology-dominated Nasdaq saw an increase of 0.45%. The HIV and hepatitis C drugmaker's stock has …
Morgan Stanley met privately with Gilead Sciences (GILD) leadership at its 2026 Global Healthcare Conference this month, and the feedback strengthened the bank's positive view on the stock. Morgan Stanley's biopharma team hosted a meeting and a management dinner with Gilead Chairman and CEO …
Gilead Sciences (NasdaqGS:GILD) expanded its royalty-free voluntary licensing of once-yearly lenacapavir for HIV prevention to 120 high-incidence countries. The biopharma group signed a regional agreement with the Pan American Health Organization to widen access to twice-yearly lenacapavir across Latin America and the Caribbean. The …
Gilead Sciences, Inc. (NASDAQ:GILD) has reached an agreement with the Pan American Health Organization (PAHO) to expand access to its twice-yearly HIV-prevention drug lenacapavir across Latin America and the Caribbean. The agreement creates a regional procurement pathway through PAHO for 14 countries, including Brazil, …
MEXICO CITY, September 17, 2026--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF), the world's largest HIV care provider, welcomes a new agreement between Gilead Sciences and the Pan American Health Organization (PAHO) that could expand access to lenacapavir for HIV prevention in 14 countries across Latin America. …
Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this HIV and hepatitis C drugmaker …
Gilead Sciences GILD has signed an agreement with the Pan American Health Organization (PAHO) to accelerate access to twice-yearly lenacapavir for HIV prevention across PAHO Member States in Latin America and the Caribbean. The agreement will use PAHO's Regional Revolving Funds to create a …
- 6 Royalty-Free Voluntary Licensing Agreements Aim to Support Potential Manufacturing Readiness and Supply in 120 High-Incidence, Resource-Limited Countries Ahead of Phase 3 PURPOSE 365 Results and Potential Regulatory Approvals - - Builds On Gilead's Ongoing Commitment to Communities Affected by HIV by Helping …
– Agreement Establishes a Regional Pathway Through PAHO's Regional Revolving Funds to Support Country-Led Adoption of Long-Acting HIV Prevention – – Partnership Advances Gilead's Global Access Strategy, Helping Turn Scientific Innovation into Public Health Impact – FOSTER CITY, Calif., September 15, 2026--(BUSINESS WIRE)--Gilead Sciences, …
This article first appeared on GuruFocus. A Comprehensive Look at the Biopharma Giant's Upcoming Payout, Yield, and Long-Term Dividend Sustainability Gilead Sciences Inc (NASDAQ:GILD) recently announced a total dividend of $0.82 per share, with the ex-dividend date set for 2026-09-15. This upcoming distribution includes …
Gilead Sciences has delivered a powerful 5 year run in its share price, and fresh headlines around new research facilities and HIV treatments keep attention firmly on its growth story. With the stock now at US$146.42, the live question for investors is whether that …
In the latest trading session, Gilead Sciences (GILD) closed at $146.42, marking a +1.88% move from the previous day. The stock's performance was ahead of the S&P 500's daily loss of 0.48%. Meanwhile, the Dow experienced a drop of 0.29%, and the technology-dominated Nasdaq …
On August 13, a federal appeals court ruled in favor of Gilead Sciences, Inc. (NASDAQ:GILD), upholding a preliminary injunction that bars the defendants from importing or facilitating the sale of foreign-market Gilead-branded medications in the US. The US Court of Appeals for the Fourth …
In the latest trading session, Gilead Sciences (GILD) closed at $146.64, marking a -2.88% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.58%. Meanwhile, the Dow experienced a drop of 1.18%, and the technology-dominated Nasdaq saw …
Assembly Biosciences, Inc. – Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes – – Cash runway remains projected into 2029, including the first $75 million collaboration extension fee from Gilead payable in Q4 …
– Brings Together Oncology, Inflammation and Research Data Science Teams to Foster Scientific Collaboration – – One of Three Foster City Projects Supporting Gilead's $32 Billion U.S. Investment and 3,000 High-Quality Domestic Jobs – FOSTER CITY, Calif., September 08, 2026--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: …
Gilead Sciences, Inc. (NASDAQ:GILD) has added another treatment to its HIV portfolio with the FDA approval of Bixlenvo, a once-daily pill for adults whose infection is already suppressed to very low levels. The combination brings together bictegravir, a key component of Gilead's (NASDAQ:GILD) blockbuster …
Company Logo One-Year Analytical Tool Delivers Deal-Grade Competitive Intelligence on 2,370+ Drugs, 1,700+ BD&L Contacts, and 208 Top Investors as the Pipeline Adds 236 New Therapies in Just 12 Months Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Unlocking Opportunity: Dominate the Market of …
Gilead Sciences (NASDAQ: GILD) has no major concerns about its HIV franchise until the next decade. That hasn't kept the pharmaceutical company from preparing for the loss of exclusivity for its legacy HIV therapies. Gilead has spent heavily on its pipeline, and that's paying …
Gilead Sciences recently secured U.S. FDA approval for Bixlenvo, a once-daily single tablet regimen for virologically suppressed adults with HIV on complex regimens, and European Commission approval for Trodelvy plus Keytruda as a first-line treatment for certain PD-L1–positive metastatic triple-negative breast cancer patients. These …
Quick Read GILD's $10 billion in 2025 free cash flow covered its $4 billion dividend twice over, earning a B+ dividend safety grade. Patent settlements pushed the earliest generic Biktarvy entry to April 2036, giving Gilead a decade-long runway to diversify revenue before the …
A month has gone by since the last earnings report for Gilead Sciences (GILD). Shares have added about 13.6% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next …
Gilead Sciences, Inc. GILD recently won FDA approval for Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. The approval makes Bixlenvo the first and only STR option for …
Search by ticker symbol or company name and select a result to open its chart.
Start typing to find a stock or ETF.
Choose one or more countries for market search, or include every covered market.
Currently searching United States